KR20230015927A - Sars-cov-2 바이러스 치료를 위한 글루코코르티코이드 수용체(gr) 조절제 - Google Patents

Sars-cov-2 바이러스 치료를 위한 글루코코르티코이드 수용체(gr) 조절제 Download PDF

Info

Publication number
KR20230015927A
KR20230015927A KR1020227041735A KR20227041735A KR20230015927A KR 20230015927 A KR20230015927 A KR 20230015927A KR 1020227041735 A KR1020227041735 A KR 1020227041735A KR 20227041735 A KR20227041735 A KR 20227041735A KR 20230015927 A KR20230015927 A KR 20230015927A
Authority
KR
South Korea
Prior art keywords
cells
icam3
sars
cov
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227041735A
Other languages
English (en)
Korean (ko)
Inventor
테레사 데이셔
스캇 웨인 맥케이
Original Assignee
에이브이엠 바이오테크놀로지, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이브이엠 바이오테크놀로지, 엘엘씨 filed Critical 에이브이엠 바이오테크놀로지, 엘엘씨
Publication of KR20230015927A publication Critical patent/KR20230015927A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020227041735A 2020-04-29 2021-04-28 Sars-cov-2 바이러스 치료를 위한 글루코코르티코이드 수용체(gr) 조절제 Pending KR20230015927A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063017199P 2020-04-29 2020-04-29
US63/017,199 2020-04-29
PCT/US2021/029608 WO2021222385A1 (en) 2020-04-29 2021-04-28 Glucocorticoid receptor (gr) modulators for treating a sars-cov-2 virus

Publications (1)

Publication Number Publication Date
KR20230015927A true KR20230015927A (ko) 2023-01-31

Family

ID=76270026

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227041735A Pending KR20230015927A (ko) 2020-04-29 2021-04-28 Sars-cov-2 바이러스 치료를 위한 글루코코르티코이드 수용체(gr) 조절제

Country Status (7)

Country Link
US (1) US20230172950A1 (https=)
EP (1) EP4142736A1 (https=)
JP (1) JP2023524434A (https=)
KR (1) KR20230015927A (https=)
CN (1) CN115666583A (https=)
BR (1) BR112022021691A2 (https=)
WO (1) WO2021222385A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024540319A (ja) * 2021-11-05 2024-10-31 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 肺粘膜炎症の処置のための低分子量ヒアルロン酸の使用
CN114028571B (zh) * 2021-11-18 2023-04-28 中国医学科学院基础医学研究所 含氮双膦酸盐联合糖皮质激素在预防或治疗病毒性肺炎中的应用
CN114099481B (zh) * 2022-01-28 2022-05-24 深圳湾实验室 雾化吸入型糖皮质激素纳米药物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3490605B1 (en) 2017-04-01 2023-06-07 AVM Biotechnology, LLC Replacement of cytotoxic preconditioning before cellular immunotherapy
EP3488851A1 (en) * 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
CA3168378A1 (en) * 2020-02-28 2021-09-02 Avm Biotechnology, Llc Lypmphocyte population and methods for producing same

Also Published As

Publication number Publication date
BR112022021691A2 (pt) 2022-12-20
CN115666583A (zh) 2023-01-31
JP2023524434A (ja) 2023-06-12
WO2021222385A1 (en) 2021-11-04
US20230172950A1 (en) 2023-06-08
EP4142736A1 (en) 2023-03-08

Similar Documents

Publication Publication Date Title
Zhou et al. Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies
US11419879B2 (en) Methods for treating and preventing viral infections
Spiteri et al. PLX5622 reduces disease severity in lethal CNS infection by off-target inhibition of peripheral inflammatory monocyte production
Saxena et al. Poly-ICLC, a TLR3 agonist, induces transient innate immune responses in patients with treated HIV-infection: a randomized double-blinded placebo controlled trial
Perri et al. Immune response against head and neck cancer: biological mechanisms and implication on therapy
Johnson et al. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis
Bajwa et al. Immune mechanisms and novel pharmacological therapies of acute kidney injury
Bardina et al. Differential roles of chemokines CCL2 and CCL7 in monocytosis and leukocyte migration during West Nile virus infection
Salti et al. Granzyme B regulates antiviral CD8+ T cell responses
Shouman et al. SARS-CoV-2-associated lymphopenia: possible mechanisms and the role of CD147
Kaushik et al. TLR4 as a therapeutic target for respiratory and neurological complications of SARS-CoV-2
Wein et al. IL-36γ protects against severe influenza infection by promoting lung alveolar macrophage survival and limiting viral replication
Zhu et al. Innate and adaptive immune response in SARS-CoV-2 infection-Current perspectives
KR20230015927A (ko) Sars-cov-2 바이러스 치료를 위한 글루코코르티코이드 수용체(gr) 조절제
Radandish et al. The role of distinct subsets of macrophages in the pathogenesis of MS and the impact of different therapeutic agents on these populations
Abston et al. TLR3 deficiency induces chronic inflammatory cardiomyopathy in resistant mice following coxsackievirus B3 infection: role for IL-4
Wang et al. Novel exosome-targeted T-cell-based vaccine counteracts T-cell anergy and converts CTL exhaustion in chronic infection via CD40L signaling through the mTORC1 pathway
Morrow et al. Stimulation of the liver X receptor pathway inhibits HIV-1 replication via induction of ATP-binding cassette transporter A1
Khan Possible protective role of 17β-estradiol against COVID-19
Thomas et al. Hidden epitopes emerge in secondary influenza virus-specific CD8+ T cell reponses
Liu et al. Role of immune cells in the pathogenesis of myocarditis
Crotty et al. Hypogammaglobulinemia and exacerbated CD8 T-cell–mediated immunopathology in SAP-deficient mice with chronic LCMV infection mimics human XLP disease
Mahajan et al. Plcγ2/Tmem178 dependent pathway in myeloid cells modulates the pathogenesis of cytokine storm syndrome
Lupfer et al. Deficiency of the NOD-Like receptor NLRC5 results in decreased CD8+ T cell function and impaired viral clearance
Choi et al. Indispensable role of CX3CR1+ dendritic cells in regulation of virus-induced neuroinflammation through rapid development of antiviral immunity in peripheral lymphoid tissues

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902